FDA Green Lights AstraZeneca, Merck's Lynparza for Metastatic Breast Cancer By Sam | January 11, 2018 Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer. Source: BioSpace Posted in BioPharma